Supplementary Figure S1 from Phase II Study of Docetaxel and Trametinib in Patients with <i>KRAS</i> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
2025-11-25
Supplementary Table S1 from Phase II Study of Docetaxel and Trametinib in Patients with <i>KRAS</i> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
2025-11-25
Supplementary Table S2 from Phase II Study of Docetaxel and Trametinib in Patients with <i>KRAS</i> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
2025-11-25
Supplementary Table S3 from Phase II Study of Docetaxel and Trametinib in Patients with <i>KRAS</i> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
2025-11-25
A Plasma Proteomics Test Predicts Immunotherapy Benefit in NSCLC Independent of Genomic Alterations
The Journal of Liquid Biopsy · 2025-11-01
Prognostic value of patient-reported outcomes for survival in patients with advanced lung cancer receiving immune checkpoint inhibitors
Frontiers in Immunology · 2025-10-21 · 1 citations
P2.06.93 Distinct Clinical and Biological Features of Five SCLC Subtypes Identified by Plasma Proteomic Analysis
Journal of Thoracic Oncology · 2025-10-01
1862P Association between patient-reported outcomes (PROs) and overall survival (OS) in aNSCLC patients treated with first-line (1L) cemiplimab-based therapy
Annals of Oncology · 2025-09-01
1991P Overall survival (OS) with sotorasib plus carboplatin and pemetrexed in KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) from the global phase Ib CodeBreaK 101 study
Annals of Oncology · 2025-09-01 · 1 citations
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024
Cancer · 2025-08-26 · 2 citations
Data from Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non–Small Cell Lung Cancer: A Lung-MAP Study
2025-08-14
Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer
Clinical Lung Cancer · 2025-08-06
Fragmentomic-based algorithm to computationally predict tumor-somatic, germline, and clonal hematopoiesis variant origin in liquid biopsy
The Journal of Liquid Biopsy · 2025-07-15 · 6 citations
Authors response to “Letter to the Editor”: “Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types”
Journal for ImmunoTherapy of Cancer · 2025-07-01 · 1 citations
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial
The Lancet Respiratory Medicine · 2025-06-24 · 10 citations
Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non–Small Cell Lung Cancer: A Lung-MAP Study
Clinical Cancer Research · 2025-06-04 · 1 citations
Costs and Benefits of Whole-Exome, Whole-Transcriptome Sequencing in Patients With Advanced Non–Small Cell Lung Cancer
JCO Precision Oncology · 2025-06-01 · 2 citations
Exploring clonal hematopoiesis (CH) of short variants (SVs) detected in liquid biopsies (LBx) in genes relevant to non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology · 2025-05-28
Prevalence of EGFR mutations in non-small cell lung cancer in Hawaii: A multi-center epidemiology study.
Journal of Clinical Oncology · 2025-05-28 · 1 citations
Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications
Journal for ImmunoTherapy of Cancer · 2025-05-01 · 3 citations